Clinical Trials on Stage I Non-Small Cell Lung Cancer AJCC v7 in Japan

Total 389 results

Masahiro Tsuboi
Eli Lilly and Company; Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Non-small Cell Lung Cancer Stage II | Non-small Cell Lung Cancer Stage IB | Non-small Cell Lung Cancer Stage ⅢA

Japan
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Limited Stage Lung Small Cell Carcinoma | Stage I Lung Cancer AJCC v8

United States, Japan
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Malignant Germ Cell Tumor | Germ Cell Tumor | Childhood Extracranial Germ Cell Tumor | Extragonadal Embryonal Carcinoma | Malignant Ovarian Teratoma | Stage I Ovarian Choriocarcinoma | Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 | Stage I Ovarian Teratoma AJCC v6 and v7 | Stage I Ovarian Yolk... and other conditions

United States, Canada, Japan, Australia, Puerto Rico, New Zealand, Saudi Arabia, United Kingdom, India
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IIA Cervical Cancer AJCC v7 | Stage IB Cervical Cancer AJCC v6 and v7 | Stage I Cervical Cancer AJCC v6 and v7 | Stage IA Cervical Cancer AJCC v6 and v7

United States, Korea, Republic of, Japan
GOG Foundation
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7

United States, Canada, Japan
Tomoshi Tsuchiya

Completed

A Feasibility Study of Oral Adjuvant Chemotherapy With S-1

Non-small Cell Lung Cancer

Japan
Hamamatsu University

Completed

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (ATTENTION)

Non-small-cell Lung Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Tokyo University
Shionogi; National Cancer Center Hospital East; Hokkaido University; Fukushima... and other collaborators

Unknown

Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer

Non-small- Cell Lung Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
National Hospital Organization Nagoya Medical Center
Merck Sharp & Dohme LLC; Central Japan Lung Study Group

Active, not recruiting

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

Non-squamous Non-small-cell Lung Cancer | Cancer, Lung

Japan
Shiga University
Tokyo University

Completed

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Shiga University
Tokyo University

Completed

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Stage IV Non-Small Cell Lung Cancer

Spain, United States, France, Japan
Shiga University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Takeda

Recruiting

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Japan
Shiga University

Completed

A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IV

Georgia, India, Romania, Spain, Germany, Japan
Pfizer

Recruiting

Safety and Efficacy of Xalkori ROS1

Non-small Cell Lung Cancer

Japan
Pfizer

Recruiting

Safety and Efficacy of Lorbrena

Non-small Cell Lung Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Kyowa Kirin Co., Ltd.

Completed

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Non-small-cell Lung Cancer

Japan
Kobe City General Hospital

Terminated

The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab

Advanced Non-small Cell Lung Cancer

Japan
Novartis Pharmaceuticals

Completed

An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of ARQ 197 in Combination With Erlotinib

Advanced/Recurrent Non-small-cell Lung Cancer

Japan
R-Pharm

Completed

Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of ARQ 197 in Combination With Erlotinib

Non-small-cell Lung Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Eisai Co., Ltd.

Completed

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Non-small-cell Lung Cancer

Japan
Wakayama Medical University
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

Japan
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Non-Small-Cell Lung Cancer

Japan
Daiichi Sankyo Co., Ltd.

Terminated

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Astellas Pharma Inc

Terminated

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer

Japan, Korea, Republic of, Taiwan
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA)

Non Small Cell Lung Cancer (Stage III)

United States, Spain, Taiwan, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Russian Federation, China, Malaysia, Argentina
Kyoto University
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Unknown

Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Japan
Eli Lilly and Company

Completed

A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients

Non Small Cell Lung Cancer

Japan
Hamamatsu University

Completed

Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer (GEEP)

Non-Small Cell Lung Cancer

Japan
Shiga University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Japan
Eli Lilly and Company

Completed

To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

Japan
Juntendo University
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Non-squamous Non-small-cell Lung Cancer | EGFR Activating Mutation

Japan
Bristol-Myers Squibb

Completed

Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer

Non-Small Cell Lung Cancer

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan

Non-Small Cell Lung Cancer

Japan
Gunma University
J~pharma

Completed

Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake (angiogenesis)

Non-Small Cell Lung Cancer | Angiogenesis

Japan
Eli Lilly and Company

Completed

A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic

Japan
Eli Lilly and Company

Completed

A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Squamous Non-small Cell Lung Cancer

Japan
Novartis Pharmaceuticals

Recruiting

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Korea, Republic of, Spain, Japan, Germany, Switzerland
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan (LIGHT-NING)

Non-Small Cell Lung Cancer

Japan
Novartis Pharmaceuticals

Completed

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Non-Small-Cell Lung Cancer

Japan
Merck Sharp & Dohme LLC

Completed

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Non-Small-Cell Lung Carcinoma

Japan

Clinical Trials on Stage I Non-Small Cell Lung Cancer AJCC v7 in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations